David Adair

David Adair has 20+ years as an angel and venture capital investor and is a founding member of Solas BioVentures, which focuses on investing in biotech and MedTech companies. He has led investments and served on the boards of Francis Medical, Biostable S&E, Arrivo Bio Ventures, NX Prenatal, Elira, InterShunt Technologies, AEGEA Medical (acquired by Cooper Surgical), Veran Medical Technologies (acquired by Olympus Corporation of America), Addrenex (acquired by Sciele/Shionogi), NeuroNex (acquired by Acorda), Velo Bio (acquired by AMAG Pharmaceuticals), Aerial Bio (acquired by Jazz Pharmaceuticals), NxThera (acquired by Boston Scientific), and Knopp BioSciences (asset purchase by Biohaven Pharmaceutical). He is also an inventor and prior c-suite operator of a device and pharmaceutical startup.

David has served more than 20 years as a practicing physician and as a professor and vice chairman of the department of obstetrics and gynecology at the University of Tennessee College of Medicine. He has a B.S. in biology from Morehead State University, an MBA from Gary W. Rollins School of Business at the University of Tennessee, Chattanooga, and an M.D. from the Joan C. Edwards College of Medicine at Marshall University.